At A Glance

Who we are
As a global leader in DNA sequencing and microarray-based solutions, we are dedicated to improving human health by unlocking the power of the genome. Our technology is responsible for generating more than 90% of the world's sequencing data.¹

Quick facts
$3.54 Billion USD (2019)  
Annual revenue
>7,800  
Number of employees
Francis deSouza  
President & CEO
San Diego, California, USA  
Headquarters
1998  
Year founded

Who we serve
We serve customers in a broad range of research, clinical, and applied markets, including:

- Oncology
- Reproductive health
- Genetic disease
- Microbiology
- Infectious disease
- Agriculture
- Molecular & cell biology

We enable the adoption of genomic solutions in settings such as:

- Universities and academic research centers
- Pharmaceutical companies
- Genome centers
- Biotechnology companies
- Hospitals
- Consumer genetics companies
- Government agencies

Where we operate

United States
- San Diego (Headquarters)
- Foster City
- Hayward
- Baltimore
- Madison
- Brazil
- São Paulo
- United Kingdom
- Cambridge
- France
- Evry
- Germany
- Berlin

Netherlands
- Eindhoven

China
- Beijing
- Shanghai

Japan
- Tokyo
- Osaka

Singapore

Australia
- Melbourne

South Korea
- Seoul
Making breakthroughs possible

Illumina has developed one of the world’s most comprehensive genomics portfolio of integrated systems, consumables, and analysis tools. With each technological breakthrough, we help scientists better understand genetic variation at all levels of complexity.

Sequencing systems

**NovaSeq™ 6000**
Production-level sequencer for any species, application, or scale of sequencing project, including genomes, exome, and transcriptomes.

**NextSeq™ 1000/2000**
Benchtop sequencer for genome sequencing, exome sequencing, transcriptome sequencing and cytogenomic and methylation array scanning.

**MiSeq™**
Benchtop sequencer for targeted and small-genome sequencing.

**MiniSeq™**
Benchtop sequencer for targeted DNA and targeted RNA sequencing.

**NextSeq™ 550Dx™**
Benchtop IVD sequencer for comprehensive cancer testing and NIPT, as well as clinical research applications, from targeted panels to exomes; cleared or approved in > 20 countries.

**MiSeq™ Dx™**
Benchtop IVD sequencer for targeted tumor profiling and genetic disease testing, as well as clinical research applications including amplicon sequencing; cleared or approved in > 20 countries.

Array scanners

**iSeq™ 100**
Benchtop sequencer for targeted gene sequencing, direct amplicon sequencing, and small-genome sequencing.

**iScan™ System**
Genotyping, CNV analysis, DNA methylation, and gene expression profiling.

Cost of sequencing, per human whole genome

<table>
<thead>
<tr>
<th>Year</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>$100 million</td>
</tr>
<tr>
<td>2020</td>
<td>$600 USD</td>
</tr>
</tbody>
</table>

Since 2001, the cost of DNA sequencing has dropped more than 100,000x from $100 million per human genome to less than $600 today. Discoveries that were unimaginable a few years ago are now becoming routine.

Notable awards

- Glassdoor Employees’ Choice Best Place to Work (2019)
- Forbes’ World’s Best Employers (2019)
- Computerworld Best Places to Work in IT (2018)
- Forbes' America's Best Midsize Employers (2018)

© 2020 Illumina, Inc. All rights reserved. PUB 070-2017-022 QB 8147